Conotoxia Review

At FXCanary, our reviews start with a relentless focus on what actually matters to traders: real-world safety, transparency, and accountability. For Conotoxia, we cross-checked every licensing claim against the public registers of the Cyprus Securities and Exchange Commission (CySEC), scrutinised the broker’s structural profile, and combed through 36 real user reviews across multiple feedback platforms. Our investigation is built on verifiable evidence, not marketing rhetoric, so you can make a clear-eyed decision.

We also analysed the broker’s disclosure gaps—missing minimum deposits, undisclosed spreads, and a company headcount of zero—alongside a pattern of consumer complaints alleging blocked accounts, frozen withdrawals, and unresponsive support. This review synthesises that evidence into a rigorous assessment, flagging every red flag we uncovered.

Conotoxia Ltd is registered at ChrysorroiaTissis 11, 3032 Limassol, Cyprus—a jurisdiction that hosts many regulated CFD brokers. Public records show the company was incorporated on 12 December 2018, though its own promotional material claims a 2013 origin; this discrepancy should alert traders to possible inconsistencies in its corporate narrative. The registered office in Limassol is a standard commercial address that does not guarantee a meaningful physical presence.

Most striking is the employee count: official sources list zero employees. For a firm offering financial services, this raises immediate questions about how it can adequately support trading operations, compliance, and customer service. While some regulated brokers outsource certain functions, a zero‑employee structure is unusual and heightens concerns about the firm’s ability to meet its obligations to clients.

Conotoxia holds a single CySEC licence (number 336/17) under a Market Making (MM) authorisation. CySEC is a full member of the European Securities and Markets Authority (ESMA), which means retail traders benefit from mandatory leverage caps (up to 1:30 for major forex pairs), negative balance protection, and access to the Investor Compensation Fund (ICF) that covers up to €20,000 of eligible claims in the event of broker insolvency. A CySEC licence is, on paper, a meaningful safeguard.

However, a Market Making licence means Conotoxia is authorised to act as the counterparty to clients’ trades, which introduces a structural conflict of interest. While this is common, the lack of transparency around execution quality and the complete absence of disclosed spreads make it impossible for a trader to gauge whether dealing‑desk practices could be prejudicial. The licence is only the starting point; a broker’s operational conduct determines genuine safety.

Conotoxia offers three account tiers: Retail, Experienced, and Professional, differentiated primarily by leverage. Retail accounts are capped at 1:30 as per ESMA rules, while Experienced offers 1:100 and Professional pushes to 1:300—levels that require traders to confirm they meet the higher capital and experience thresholds mandated by CySEC. The absence of any disclosed minimum deposit for any tier is a glaring omission; traders are being asked to open an account without a clear idea of the financial commitment required.

Even more concerning, the broker provides zero information on spreads or commission structures. The only instrument category listed is ‘Forex pairs’, with no further breakdown of specific pairs, typical spreads, swaps, or other costs. This opacity makes any meaningful cost comparison impossible and forces traders to commit funds blindly. For a CySEC‑regulated entity, this level of non‑disclosure is well below industry norms and suggests either intentional reticence or a product not yet fully operational.

Conotoxia does not publicly list any deposit or withdrawal methods—a fundamental piece of information every prospective client needs before funding an account. Our research did not uncover any clear banking partners or payment processor integrations, which is unusual for a firm advertising payment and forex services. The lack of transparency around funding channels is a practical barrier to entry and a significant trust deficit.

The real‑user record amplifies these concerns. Of the two withdrawal‑related complaints we identified, one explicitly warns: “Stay away, in EU they went bankrupt and do NOT process any withdrawals, evacuate your money as soon as you can.” Other reviews describe transfers that “vanished into thin air” and accounts blocked with no refund. The pattern is stark: when traders attempt to recover their money, they face silence, unexplained delays, and outright refusal to honour withdrawal requests.

The only trading instruments documented are Forex pairs; there is no mention of indices, commodities, cryptocurrencies, or share CFDs in the structured disclosures we obtained—despite the broker’s own description claiming a broad range. The platform itself is not specified, be it MetaTrader, a proprietary app, or a web‑based interface, leaving traders in the dark about the tools and charting they will have access to. User reviews paint a grim picture: a customer who had used Conotoxia for four years reports that in recent months “the service has drastically declined,” with transfers that used to be immediate now taking days, and one reviewer describes the platform as a “hoax.”

Without verifiable platform specifications, real‑time execution data, or a demonstrated track record of reliable uptime, it is impossible to recommend Conotoxia for active trading. The company’s zero‑employee headcount also raises the question of who is maintaining and updating the trading infrastructure—a critical risk for any trader expecting consistent access to the markets.

Conotoxia’s cost structure is a black box. No minimum spreads—fixed or variable—are published, and there is no information on commissions, overnight swaps, or inactivity fees. User complaints, however, fill in some of the blanks.

One reviewer notes that even when a transaction does not complete, the broker still levies cancellation fees, with customer service pointing to “buried” terms. Another had their account blocked without explanation, leaving them unable to access their funds for everyday expenses. Trustpilot reviews accuse the firm of “stealing” via stalled currency conversions and of being a “very bad bank.”

When a broker refuses to disclose its fee schedule, it shifts all value risk onto the client. The combination of hidden fees and a documented history of unexplained account blocks creates an environment where the true cost of doing business with Conotoxia cannot be assessed in advance—a situation that should be unacceptable to any retail trader.

Across multiple platforms, Conotoxia holds a Trustpilot rating of 1.5 out of 5 from 36 reviews—a score that indicates systemic dissatisfaction rather than isolated grievances. The most heavily mentioned topic is customer support, with 16 negative mentions out of 17. Traders describe being ignored for days or weeks, with one stating that they called seven times in a single day without answer. The few positive reviews are brief and generic (e.g., “Really good bank with all the services you need”), while detailed negatives consistently report money disappearing and support evaporating once problems arise.

The second most common complaint is order execution, with five negative mentions and no positives. Reviews speak of transfers “in execution” for months, with funds effectively locked and untouchable. One user reports a transfer from a UK bank to their Conotoxia wallet that “vanished” on 21 October, with no response by phone or email. Another who had a positive four‑year history now describes a “drastic decline” in service speed and reliability. These are not stories of typical market delays; they describe a breakdown in basic transactional integrity.

Scam concerns feature in seven out of seven negative mentions, with users directly calling Conotoxia “top scammers” and warning others to stay away from “all payments connected with this company.” Account‑blocking is a recurring theme: several reviewers state their accounts were closed shortly after submitting KYC documents or for “no reason,” with funds not returned. One ex‑client summarises: “Bunch of crooks. Closed my account and never refunded me in full.” The weight of these firsthand accounts is damning.

The sheer volume of fraud allegations—seven out of seven negative mentions—is a red flag that cannot be dismissed as isolated frustration. Users specifically warn that Conotoxia works with “fraudulent companies and fraud schemes,” and that in the EU the broker “went bankrupt and do NOT process any withdrawals.” These claims, combined with the fact that the company lists zero employees, point toward a hollow operational shell that can disappear at the first sign of financial pressure.

Our investigation also noted the absence of any public financial statements or evidence of the capital reserves required by a CySEC licensee. While a CySEC licence provides a formal framework, a firm that effectively has no staff and a pattern of blocking client withdrawals is not functioning as a going‑concern financial institution. The discrepancy between the 2018 incorporation date and the claimed 2013 registration further undermines credibility. For any trader, the risk of permanent loss of capital is unacceptably high.

Our analysis assigns Conotoxia a Scam Risk Score of 32 out of 100, categorising it as ‘Guarded’. This rating reflects a broker that holds a legitimate top‑tier licence but fails on almost every operational and transparency metric. The CySEC licence provides a theoretical safety net, but the real‑world evidence of blocked accounts, vanishing deposits, and a non‑existent support structure indicates that the licence is not being backed by substantive, client‑focused operations.

We recommend that retail traders avoid Conotoxia entirely. The lack of disclosed pricing, funding methods, and platform information, combined with a Trustpilot rating of 1.5 and a zero‑employee profile, makes the chance of a smooth trading experience remote. For anyone already holding an account with Conotoxia and struggling to withdraw, immediate steps should include filing a formal complaint with the company in writing, then escalating to the Cyprus Financial Ombudsman and CySEC if no response is received. Do not deposit additional funds. The priority must be retrieval, not profit.